Semnur Pharmaceuticals, Inc. (SMNR) Fair Value 2026

SMNR · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-27, Semnur Pharmaceuticals, Inc. (SMNR) trades at $0.58. QOC: 4.3/10. Value Trap Risk: 21/100 (SAFE). 0/13 models active.

Key Facts

Ticker
SMNR
Price
$0.58
Quality Score
4.3/10
Value Trap Risk
21/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

What Fair Value Does Each Model Give SMNR?

0 Intrinsic Value Models vs. Current Price ($0.58)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Semnur Pharmaceuticals, Inc. (SMNR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Semnur Pharmaceuticals, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About SMNR?

0 of 13 models are currently active for SMNR. See which stocks rank higher →

How Does SMNR Rank in Pharmaceutical Preparations?

Among 6 Pharmaceutical Preparations stocks, SMNR ranks #4 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Semnur Pharmaceuticals, Inc., metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.

Is SMNR a Value Trap?

CirclFi's Value Trap algorithm assigns SMNR a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Semnur Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Semnur Pharmaceuticals, Inc. scores 4.3 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SMNR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Semnur Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

5 related Pharmaceutical Preparations stocks with 13-model coverage

CVSICV Sciences, Inc.QOC 5.4DAREDaré Bioscience, Inc.QOC 5.2CVKDCadrenal Therapeutics, Inc.QOC 5.0TOVXTheriva Biologics, Inc.QOC 4.2SVASinovac Biotech Ltd.QOC 2.9

Read investment analysis: CVSI · DARE · CVKD · TOVX · SVA

Which Other Stocks Have a Similar Quality Score to SMNR?

7 companies across all industries closest to SMNR’s Quality of Company score of 4.3/10.

HYMCHycroft Mining Holding CorporationQOC 4.3POSCPositron CorporationQOC 4.3AIEVThunder Power Holdings, Inc.QOC 4.3NEXTNextDecade CorporationQOC 4.3PALProficient Auto Logistics, Inc.QOC 4.3BRVOBravo Multinational IncorporatedQOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HYMC · POSC · AIEV · NEXT · PAL · BRVO · NVDA

What Else Do Investors Ask About Semnur Pharmaceuticals, Inc.’s Valuation?

What is Semnur Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Semnur Pharmaceuticals, Inc. (SMNR). The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SMNR overvalued or undervalued right now?

At $0.58, 0 of 0 active models suggest SMNR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Semnur Pharmaceuticals, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.3 mean for SMNR?

Semnur Pharmaceuticals, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on SMNR?

CirclFi analyzes SMNR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is SMNR a value trap in 2026?

Semnur Pharmaceuticals, Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Semnur Pharmaceuticals, Inc. (SMNR) a Quality of Company score of 4.3/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/SMNR/ · Methodology
Primary sources for this SMNR valuation
  • Financial statements: Semnur Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001913577) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SMNR as of ; valuations recomputed .